Erleada, first-and-only next-generation androgen receptor inhibitor with once-daily, single-tablet option, now available in the U.S.

The introduction of the 240mg tablet provides the first-and-only option for a once-daily, single-tablet Androgen Receptor Inhibitor (ARI) approved for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).

With two strengths available, healthcare professionals will have the flexibility to prescribe the approved 240mg once-daily dose of Erleada in either one 240mg tablet or four 60mg tablets. The single-tablet option may be preferable for patients in need of reducing their total number of daily pills.

Erleada remains the only ARI with labeling to include approved alternate methods of administration for patients who have difficulty swallowing tablets whole. The 60mg tablets continue to have an approved option for dispersing with applesauce, while the 240mg tablet is approved for dispersing in orange juice, water or applesauce. The 240mg tablet may also be administered through a feeding tube.